 A substantial proportion of patients with head and neck HNC are not suitable for curative treatment with surgery andor chemoradiotherapy CRT because of very advanced stage, significant comorbidities, bad general condition, distant metastasis, or a combination of these factors. Although radiotherapy RT is a commonly used option to achieve durable disease control and to alleviate troublesome symptoms, the data about the optimal radiation scheme and the impact of these schedules on quality of life QoL of these vulnerable patients is extremely scarce. 